Seekingalpha
Published September 12, 2026
Neuronetics a new buy at B Riley on interventional psychiatry platform | Seeking Alpha
ketamine , which has hallucinogenic effects. Spravato's US sales surpassed a $2B run rate in Q1. He noted that the company has replaced executives.
Read the full story at Seekingalpha
Surfaced by this Google Alert
- Ketamine
